[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100510375":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":10,"centralContacts":19,"locations":28,"responsibleParty":42,"collaborators":10,"id":46,"slug":47,"hasResults":48,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":10,"eligibilityCriteria":52,"healthyVolunteers":48,"sex":53,"minAge":54,"maxAge":55,"enrollmentInfo":56,"targetDuration":59,"studyType":60,"phases":10,"briefSummary":61,"conditions":62,"keywords":10,"overallStatus":30,"whyStopped":10,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":73},{"fullName":5,"class":6},"Beth Israel Deaconess Medical Center","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Lecanemab",null,"Patients with Alzheimer Disease receiving anti-amyloid mAb therapy at the BIDMC",[13],"Drug: Lecanemab",[15],{"type":16,"name":9,"description":17,"armGroupLabels":18,"otherNames":10},"DRUG","Observational study",[9],[20,25],{"name":21,"role":22,"phone":23,"phoneExt":10,"email":24},"Dan Z Press, MD","CONTACT","(617) 667-4074","dpress@bidmc.harvard.edu",{"name":26,"role":22,"phone":23,"phoneExt":10,"email":27},"Chun Lim, MD","clim@bidmc.harvard.edu",[29],{"facility":5,"status":30,"city":31,"state":32,"zip":33,"country":34,"countryCode":35,"cosmosGeoPoint":36,"geoPoint":41,"contacts":10},"RECRUITING","Boston","Massachusetts","02215","United States","US",{"type":37,"coordinates":38},"Point",[39,40],-71.05977,42.35843,{"lat":40,"lon":39},{"type":43,"investigatorFullName":44,"investigatorTitle":45,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"PRINCIPAL_INVESTIGATOR","Daniel Press","Chief, Cognitive Neurology Unit","100510375","cognitive-neurology-unit-clinical-registry-100510375",false,"NCT05925621","Cognitive Neurology Unit Clinical Registry","Cognitive Neurology Unit's Anti-amyloid Monoclonal Antibodies for the Treatment of Alzheimer's Disease Clinical Registry","Inclusion Criteria:\n\n* o Patient meets clinical criteria for mild cognitive impairment or early dementia from Alzheimer's disease\n\n  * Patient has evidence of cognitive impairment on neuropsychological testing\n  * Patient has not progressed to the moderate stage of dementia based on neuropsychological testing or clinical judgement\n  * Amyloid PET imaging and\u002For CSF analysis consistent with Alzheimer's disease\n  * Amyloid PET imaging positive\n  * CSF p-Tau\u002FAbeta42 ration \\>0.023 and ABeta42 \\\u003C 1027\\*\\*\n  * 3T MRI in past 6 months\n  * Patient has a care partner\n  * Patient under the care of an appropriate BI-Lahey amyloid clinic\n  * Patient is on a stable medication regimen\n\nExclusion Criteria:\n\n* o Recent stroke or suspected TIA in the past year\n\n  * Pregnancy\n  * Active autoimmune or immunological disease\n  * Systemic treatment with immunosuppressants, immunoglobulins, or monoclonal antibodies or their derivatives\n  * Bleeding disorder with Plts \\\u003C 50,000 or INR \\> 1.5\n  * On warfarin, heparin, or DOAC\n  * On dual antiplatelet therapy\n  * Non Alzheimer disease cause of dementia\u002FMCI\n  * ApoE e4 homozygote","ALL","50 Years","95 Years",{"count":57,"type":58},500,"ESTIMATED","30 Months","OBSERVATIONAL","A Prospective Comparative Study Of Monoclonal Antibodies For The Treatment Of Alzheimer's Disease",[63],"Alzheimer Disease","2026-04-08",{"date":66,"type":67},"2026-04-13","ACTUAL",{"date":69,"type":67},"2023-07-16",{"date":71,"type":58},"2028-06",{"name":5,"class":6},1]